Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine

The coronavirus disease 2019 (COVID-19) pandemic imposes an urgent and continued need for the development of safe and cost-effective vaccines to induce preventive responses for limiting major outbreaks around the world. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we repur...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkayyal, Almohanad A., Darwish, Manar, Ajina, Reham, Alabbas, Saleh Y., Alotaibi, Mohammed A., Alsofyani, Abeer, Bokhamseen, Maha, Hakami, Maumonah, Albaradie, Omar A., Moglan, Abdulaziz M., Hala, Sharif, Alsahafi, Abdullah Faisal, Zakri, Samer, Almuzaini, Adnan, Alsharari, Khamis, Kaboha, Feras, Taher, Mustafa Y., Zein, Haggag S., Alroqi, Fayhan, Mahmoud, Ahmad Bakur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390216/
https://www.ncbi.nlm.nih.gov/pubmed/37528991
http://dx.doi.org/10.3389/fbioe.2023.1150892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390216/
https://www.ncbi.nlm.nih.gov/pubmed/37528991
http://dx.doi.org/10.3389/fbioe.2023.1150892

Ejemplares similares